Page 1

PRESS RELEASE BIOMÉRIEUX bioMérieux - First - Quarter 2021 Business Review " First - quarter organic growth of 16.5 % at constant exchange rates and scope of consolidation : € 845 million in sales Up 9.9 % as reported Molecular biology up 19 % over the quarter , with a slowdown in BIOFIRE® respiratory panels ' demand in the US at period end Strong 28 % growth in Immunoassays , driven by COVID - related and certain emergency assays , combined with a confirmed recovery in routine parameters Solid 14 % growth in Industrial Applications , Microbiology returns to growth 2021 Outlook : first - half and full - year 2021 sales guidance adjusted slightly , as the improvement in the health situation in the US is reducing demand for BIOFIRE® respiratory panels : First - half sales are now expected to grow at around 10 % , at constant exchange rates and scope of consolidation . In a very uncertain environment with contrasted evolution of the pandemic , full year sales are now expected to grow organically at neutral to mid - single digit rate . Despite the high level of uncertainty , the annual guidance for contributive operating income is maintained . Alexandre Mérieux , Chairman and Chief Executive Officer , said : “ In a persistently uncertain business environment , consolidated sales are growing more than 16 % in the first quarter of 2021. However , the health situation is still evolving and giving rise to very unpredictable trends prompting us to update our outlook . Nevertheless , we are confident in our strategy focus on infectious diseases through diverse applications and a broad geographic footprint . " Marcy l'Étoile ( France ) , April 27th , 2021 – bioMérieux , a world leader in the field of in vitro diagnostics , today releases its business review for the three months ended March 31 , 2021 . SALES Consolidated sales total € 845 million in the first quarter of 2021 , up 9.9 % from € 769 million in the year - earlier period . Organic growth ( at constant exchange rates and scope of consolidation ) stands at 16.5 % , lifted by the very solid growth in Molecular biology ( up18.7 % ) , in Immunoassays ( up 28 % ) and Industrial Applications ( up 14.5 % ) , as well as very robust performance in the Asia Pacific region , Latin America and Africa . Exchange rate movements result in a negative currency effect of € 51 million , primarily reflecting the devaluation of the US dollar and to a lesser extent , certain Latin America and ASPAC currencies . Note : Unless otherwise stated , growth is expressed year - on - year at constant exchange rates and scope of consolidation ( like - for - like ) .